SEC Form 4 · accession 0001213900-17-003807
Icagen, Inc. · ICGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Timothy Tyson
Director
Period of report
Apr 13, 2017
Accepted (ET)
Apr 14, 2017 · 4:22 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001518520
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| WarrantF1 | $3.50 | Apr 12, 2017 | A | 75,000 | A | Apr 13, 2017 | Apr 12, 2022 | Common Stock | 75,000 | 75,000 | I |
Explanation of responses
- F1The warrants (the "Warrants") were issued to the reporting person by Icagen, Inc. (the "Company") in a private placement offering of units (the "Units" and each a "Unit") with each Unit sold at a price of $10,000 per Unit and each Unit consisting of (i) a note in the principal amount of $10,000, and (ii) a five year warrant to acquire 1,500 shares of the Company's common stock, par value, $0.001 per share ("Common Stock"), at an exercise price of $3.50 per share. Each Warrant is exercisable for one share of Common Stock. The reporting person has the right to exchange the Warrants for a like number of warrants to be issued to the lender in the Company's next debt financing.